Ryo Atsumi

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1K citations · Full text

Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes

Pieter J. Gaillard, Levina Helena Voorwinden, Jette Lyngholm Nielsen et al. · European Journal of Pharmaceutical Sciences · 2001 · 331 citations

Neurophysiology, Blood–brain Barrier, Vitro Model +11

A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding

Shintaro Nakayama, Ryo Atsumi, Hideo Takakusa et al. · Drug Metabolism and Disposition · 2009 · 246 citations

Drug Safety, Substance Abuse, Predictive Toxicology +8

Metabolic Activation of CPT-11, 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase.

T Satoh, Masakiyo Hosokawa, Ryo Atsumi et al. · Biological and Pharmaceutical Bulletin · 1994 · 173 citations · Full text

Identification of Influx Transporter for the Quinolone Antibacterial Agent Levofloxacin

Tomoji Maeda, Koichi Takahashi, Naoko Ohtsu et al. · Molecular Pharmaceutics · 2006 · 111 citations